Semaglutide 2.5 mg and 5 mg are both compounded doses above the FDA-approved maximums. The 2.5 mg dose closely approximates the maximum Wegovy maintenance dose (2.4 mg), so the difference is clinically insignificant. The 5 mg dose is approximately twice the FDA-approved maximum, and limited safety or efficacy data exist for this dose. Below is a head-to-head comparison and what’s known about the trade-offs.
FDA-Approved Maximum Doses
For context on what’s standard:
- Ozempic (diabetes): maximum 2 mg weekly
- Wegovy (weight loss): maximum 2.4 mg weekly
- Rybelsus (diabetes oral): maximum 14 mg daily
The 2.5 mg dose slightly exceeds Wegovy’s maximum approved dose (by 0.1 mg). The 5 mg dose is roughly double the maximum approved dose.
2.5 MG: Practically Equivalent to Wegovy Maximum
2.5 mg is widely used in compounded semaglutide because:
- It closely approximates the maximum Wegovy dose of 2.4 mg
- The round number makes unit-to-mg math easier (100 units at 2.5 mg/mL concentration delivers 2.5 mg)
- The 0.1 mg difference from 2.4 mg is clinically insignificant and within typical dose-to-effect variability
- Compounding pharmacies often produce 2.5 mg/mL concentrations as a standard offering
For practical purposes, 2.5 mg can be treated as equivalent to the maximum approved Wegovy dose. Efficacy, side effects, and risk profile should mirror what’s documented for 2.4 mg in clinical trials.
5 MG: Above the Approved Range
5 mg per week is approximately twice the FDA-approved maximum semaglutide dose. Important considerations:
- Not FDA-studied: safety and efficacy data at this dose are limited or absent
- Diminishing returns: dose-response curves for GLP-1 drugs plateau at higher doses; doubling the dose does not double the effect
- Increased side effects: nausea, vomiting, diarrhea, and constipation rates increase substantially at higher doses
- Unknown long-term risks: the 5 mg dose has not been studied in long-term outcome trials
The FDA has issued warnings about compounded semaglutide dosing errors and unsubstantiated claims about higher-dose formulations.
Efficacy: What the Limited Data Show
Dose-response data from semaglutide development:
| Dose | Approximate Weight Loss (68 weeks) |
|---|---|
| 0.25 mg | ~3% |
| 0.5 mg | ~6% |
| 1.0 mg | ~9% |
| 1.7 mg | ~12% |
| 2.4 mg | ~15% |
| 3.0 mg (limited data) | ~16-17% |
| 5.0 mg (estimated) | marginal additional benefit, increased side effects |
The curve flattens at higher doses. Going from 2.4 mg to 5 mg might produce 1-3 percentage points of additional weight loss in some patients, with substantially more side effects.
Side Effects at Higher Doses
Higher doses increase the rates of nausea, vomiting, diarrhea, and other GI symptoms. Trial data at higher doses are limited, but case reports and clinical observations suggest:
- Nausea rates approach 50-60% at 5 mg vs ~44% at 2.4 mg
- Vomiting and diarrhea rates increase proportionally
- Discontinuation from intolerable side effects increases
- Risk of dehydration and acute kidney injury increases (especially with persistent vomiting)
- Risk of pancreatitis may increase (though absolute rates remain low)
Why Some Patients Try Higher Doses
Patients sometimes seek higher doses because:
- Weight loss plateaued at the maximum approved dose
- Subjective belief that “more is better”
- Marketing claims from compounding pharmacies
- Hope of avoiding switching to tirzepatide
For most patients, the better alternative is switching to tirzepatide (which has FDA-approved doses up to 15 mg and stronger head-to-head efficacy data) rather than pushing semaglutide above its approved maximum.
Practical Considerations
If you’re using or considering 5 mg semaglutide:
- Discuss with your prescriber. Off-label dosing should be a medical decision, not a self-directed escalation.
- Verify compounding pharmacy. Licensing, FDA designation, and quality standards vary.
- Understand the dosing math. 5 mg at common concentrations: 50 units at 10 mg/mL, 100 units at 5 mg/mL, 200 units at 2.5 mg/mL (requires multi-mL syringe).
- Track side effects. Be ready to reduce dose if symptoms become intolerable.
- Consider tirzepatide instead. FDA-approved up to 15 mg with stronger trial data.
- Maintain hydration and nutrition. Higher doses amplify GI effects that can cause dehydration.
FDA Position on Compounded High-Dose Semaglutide
The FDA has issued repeated warnings about compounded GLP-1 medications:
- Compounded products are not FDA-reviewed for safety, efficacy, or quality
- Dosing errors are a leading cause of compounded GLP-1 adverse event reports
- High-dose marketing claims often exceed evidence base
- The legal pathway for routine compounding narrowed after the shortage ended in 2024-2025
If you have specific safety concerns or experience adverse events, report to FDA MedWatch.
The Bottom Line
Semaglutide 2.5 mg approximates the maximum FDA-approved Wegovy dose (2.4 mg) and is clinically equivalent. Semaglutide 5 mg is approximately twice the maximum approved dose; limited safety and efficacy data exist at this dose. Higher doses produce diminishing additional weight loss with substantially more side effects. For patients seeking more weight loss than 2.4 mg semaglutide provides, switching to tirzepatide (FDA-approved up to 15 mg) is generally a better option than pushing semaglutide above its approved maximum. Consult your prescriber before changing doses. For more on GLP-1 treatment options, see our hub.
